Alloy Therapeutics raises $40M Series E to build full-stack AI biotech infrastructure across 17 time zones

Alloy Therapeutics has closed a $40M Series E, its first raise since 2022, to expand what founder Errik Anderson describes as full-stack biotech infrastructure spanning 17 time zones, with operations in the US, Japan, the UK, Saudi Arabia, UAE, and Qatar.

The company sits at the intersection of wet-lab drug discovery and AI-driven data analysis, working with both large pharma and small virtual biotechs. Anderson's core argument is that the industry has split into two camps that each need what the other has: tech-bio companies with strong AI and machine learning capabilities but thin biological expertise, and traditional pharma and biotech with deep domain knowledge but underdeveloped data infrastructure. Alloy's pitch is that bridging those two sides accelerates how fast new drugs get discovered and tested.

“We're a biotech infrastructure company that works with companies all over the world helping people discover and develop drugs. We will cure everything that is curable in the next three decades — it's really just a question of how fast we can accelerate. Our last round was in 2022; since then, we've built operations across 17 time zones.”

The data and lab constraint

Anderson frames the current moment as an explosion in data generation, driven by falling DNA sequencing costs, wearables like Oura Ring and Apple Watch, and tools like Function Health. The bottleneck isn't ideation anymore. AI can generate far more drug candidates than labs can test. The design-build-test loop in wet labs remains the physical constraint, and making sense of the data that loop produces is where machine learning earns its keep.

He also notes Amazon has entered this space, with AWS launching a service connecting generative AI drug design tools to protein manufacturing and testing back-ends. His read is that AWS is primarily interested in capturing the compute traffic from in silico work, then routing it to third-party labs rather than building wet-lab capability itself.

M&A and the offshore shift

Biotech M&A is running at its strongest pace since 2019, driven partly by GLP-1 profits but more structurally by pharma's need to restock pipelines as drugs go off-patent. Big pharma is sitting on what Anderson describes as the largest capital reserves it has ever held, and most of that innovation is being sourced from small external companies. The headwind for domestic biotech is that deal flow is increasingly going to assets developed outside the US, as pharma acquires overseas and offshoring of drug discovery accelerates.

Biosecurity and the 100-day ambition

On the biosecurity question, Anderson points to a "100-day" initiative, in which Alloy and peers work toward being able to go from identifying a biological threat to having a drug ready within 100 days. He frames this as supply chain resilience rather than restriction, with the goal of keeping all critical discovery and development capabilities accessible on US soil.

Outlook

Anderson is bullish enough to say he expects every curable disease to be cured within three decades, possibly faster. He draws a direct parallel to the first internet cycle, where most bets failed but the ones that didn't reshaped the world. The $40M now funds the infrastructure he's built across those 17 time zones, with the Middle East operations he flags as a current headwind but a long-term bet.